NRIX
Nurix Therapeutics, Inc.$23.63+0.03 (+0.13%)Prev Close$23.60·MCap$2.45B·P/E—·Vol840.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
26
$4.10M
◆
Net Activity
Net Seller
$4.10M
●
Active Insiders
3
last 12 mo
Over the past 12 months, insider activity at Nurix Therapeutics, Inc. (NRIX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 26 insider sales totaling $4.10M. The most recent insider transaction was by Hansen Gwenn (officer: Chief Scientific Officer), who sold $90.0K worth of shares on Jul 30, 2026. Nurix Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.45B.
NRIX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 |
| Jul 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 |
| Jul 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 |
| Jul 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 11,008 | $23.56 | $259.4K | 13,579-45% |
| Jun 25, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,935 | $20.06 | $580.5K | 13,579-68% |
| Jun 25, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 5,394 | $20.00 | $107.9K | 115,005 |
| Jun 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.60 | $135.3K | 13,579-38% |
| May 5, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 14,055 | $16.60 | $233.3K | 38,174-27% |
| May 4, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.96 | $138.2K | 18,305-31% |
| May 1, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,394 | $16.76 | $90.4K | 26,453 |
| Apr 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,214 | $16.65 | $53.5K | 120,399 |
| Apr 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,388 | $16.65 | $39.7K | 51,647 |
| Apr 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,214 | $16.65 | $53.5K | 31,847 |
| Mar 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $15.44 | $125.8K | 34,601 |
| Feb 9, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,522 | $16.66 | $475.2K | 42,749-40% |
| Jan 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 9,790 | $16.60 | $162.5K | 83,770 |
| Jan 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,842 | $16.60 | $146.8K | 57,098 |
| Jan 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 7,322 | $16.60 | $121.5K | 45,500 |
| Jan 20, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 7,520 | $18.42 | $138.5K | 50,897 |
| Dec 18, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,760 | $17.90 | $67.3K | 0 |
| Nov 24, 2025 | Ring Christine | Chief Legal Officer | Sell | 37,600 | $17.07 | $641.7K | 0 |
| Nov 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,284 | $12.56 | $78.9K | 0 |
| Oct 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,087 | $12.80 | $52.3K | 0 |
| Oct 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,644 | $12.80 | $46.6K | 0 |
| Oct 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 3,130 | $12.80 | $40.1K | 0 |
| Aug 1, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,402 | $11.03 | $59.6K | 0 |
| Jul 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,308 | $12.01 | $51.7K | 0 |
| Jul 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,841 | $12.01 | $46.1K | 0 |
| Jul 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 4,304 | $12.01 | $51.7K | 0 |
| May 2, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,198 | $11.33 | $70.2K | 0 |
| Apr 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,377 | $11.50 | $38.8K | 0 |
| Apr 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 2,894 | $11.50 | $33.3K | 0 |
| Apr 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,438 | $11.50 | $28.0K | 0 |
| Mar 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,825 | $14.49 | $84.4K | 0 |
| Feb 3, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.95 | $114.9K | 32,638 |
| Jan 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,690 | $19.85 | $73.3K | 56,270 |
| Jan 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,220 | $19.85 | $63.9K | 32,829 |
| Jan 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,811 | $19.85 | $55.8K | 39,803 |
| Jan 2, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.50 | $112.3K | 28,084 |
| Dec 2, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $21.73 | $125.2K | 28,084 |
| Nov 4, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 28,084 |
| Nov 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $24.28 | $139.9K | 28,084 |
| Nov 1, 2024 | van Houte Hans | Chief Financial Officer | Sell | 3,546 | $24.28 | $86.1K | 33,724 |
| Oct 30, 2024 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,437 | $24.31 | $83.5K | 50,670 |
| Oct 30, 2024 | Ring Christine | Chief Legal Officer | Sell | 4,182 | $24.31 | $101.6K | 28,084 |
| Oct 30, 2024 | van Houte Hans | Chief Financial Officer | Sell | 2,368 | $24.30 | $57.6K | 37,270 |
| Oct 15, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 24,592 |
| Oct 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $22.23 | $128.0K | 24,892 |
| Sep 3, 2024 | Ring Christine | Chief Legal Officer | Sell | 9,050 | $24.94 | $225.7K | 24,792-27% |
| Aug 26, 2024 | Ring Christine | Chief Legal Officer | Sell | 9,870 | $25.01 | $246.8K | 24,592-29% |
Showing 1–50 of 133
1 / 3
NRIX Insider Buying Activity
The following table shows recent insider purchases of Nurix Therapeutics, Inc. (NRIX) stock reported via SEC Form 4 filings.
No insider buying activity found for NRIX in the last 12 months.
NRIX Insider Selling Activity
The following table shows recent insider sales of Nurix Therapeutics, Inc. (NRIX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 |
| Jul 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 |
| Jul 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 |
| Jul 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 11,008 | $23.56 | $259.4K | 13,579-45% |
| Jun 25, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,935 | $20.06 | $580.5K | 13,579-68% |
| Jun 25, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 5,394 | $20.00 | $107.9K | 115,005 |
| Jun 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.60 | $135.3K | 13,579-38% |
| May 5, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 14,055 | $16.60 | $233.3K | 38,174-27% |
| May 4, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $16.96 | $138.2K | 18,305-31% |
| May 1, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 5,394 | $16.76 | $90.4K | 26,453 |
| Apr 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 3,214 | $16.65 | $53.5K | 120,399 |
| Apr 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 2,388 | $16.65 | $39.7K | 51,647 |
| Apr 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 3,214 | $16.65 | $53.5K | 31,847 |
| Mar 2, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,148 | $15.44 | $125.8K | 34,601 |
| Feb 9, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 28,522 | $16.66 | $475.2K | 42,749-40% |
| Jan 30, 2026 | Hansen Gwenn | officer: Chief Scientific Officer | Sell | 9,790 | $16.60 | $162.5K | 83,770 |
| Jan 30, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 8,842 | $16.60 | $146.8K | 57,098 |
| Jan 30, 2026 | van Houte Hans | officer: Chief Financial Officer | Sell | 7,322 | $16.60 | $121.5K | 45,500 |
| Jan 20, 2026 | Ring Christine | officer: Chief Legal Officer | Sell | 7,520 | $18.42 | $138.5K | 50,897 |
| Dec 18, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,760 | $17.90 | $67.3K | 0 |
| Nov 24, 2025 | Ring Christine | Chief Legal Officer | Sell | 37,600 | $17.07 | $641.7K | 0 |
| Nov 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,284 | $12.56 | $78.9K | 0 |
| Oct 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,087 | $12.80 | $52.3K | 0 |
| Oct 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,644 | $12.80 | $46.6K | 0 |
| Oct 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 3,130 | $12.80 | $40.1K | 0 |
| Aug 1, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,402 | $11.03 | $59.6K | 0 |
| Jul 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,308 | $12.01 | $51.7K | 0 |
| Jul 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,841 | $12.01 | $46.1K | 0 |
| Jul 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 4,304 | $12.01 | $51.7K | 0 |
| May 2, 2025 | van Houte Hans | Chief Financial Officer | Sell | 6,198 | $11.33 | $70.2K | 0 |
| Apr 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,377 | $11.50 | $38.8K | 0 |
| Apr 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 2,894 | $11.50 | $33.3K | 0 |
| Apr 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,438 | $11.50 | $28.0K | 0 |
| Mar 3, 2025 | van Houte Hans | Chief Financial Officer | Sell | 5,825 | $14.49 | $84.4K | 0 |
| Feb 3, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.95 | $114.9K | 32,638 |
| Jan 30, 2025 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,690 | $19.85 | $73.3K | 56,270 |
| Jan 30, 2025 | Ring Christine | Chief Legal Officer | Sell | 3,220 | $19.85 | $63.9K | 32,829 |
| Jan 30, 2025 | van Houte Hans | Chief Financial Officer | Sell | 2,811 | $19.85 | $55.8K | 39,803 |
| Jan 2, 2025 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $19.50 | $112.3K | 28,084 |
| Dec 2, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $21.73 | $125.2K | 28,084 |
| Nov 4, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 28,084 |
| Nov 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $24.28 | $139.9K | 28,084 |
| Nov 1, 2024 | van Houte Hans | Chief Financial Officer | Sell | 3,546 | $24.28 | $86.1K | 33,724 |
| Oct 30, 2024 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,437 | $24.31 | $83.5K | 50,670 |
| Oct 30, 2024 | Ring Christine | Chief Legal Officer | Sell | 4,182 | $24.31 | $101.6K | 28,084 |
| Oct 30, 2024 | van Houte Hans | Chief Financial Officer | Sell | 2,368 | $24.30 | $57.6K | 37,270 |
| Oct 15, 2024 | Ring Christine | Chief Legal Officer | Sell | 3,290 | $25.00 | $82.3K | 24,592 |
| Oct 1, 2024 | Ring Christine | Chief Legal Officer | Sell | 5,760 | $22.23 | $128.0K | 24,892 |
| Sep 3, 2024 | Ring Christine | Chief Legal Officer | Sell | 9,050 | $24.94 | $225.7K | 24,792-27% |
| Aug 26, 2024 | Ring Christine | Chief Legal Officer | Sell | 9,870 | $25.01 | $246.8K | 24,592-29% |
NRIX Insiders
Similar Stocks to NRIX
VRTX
Vertex Pharmaceuticals Incorporated
$479.25-0.84%
$121.16B
REGN
Regeneron Pharmaceuticals, Inc.
$733.89+5.54%
$67.58B
RVMD
Revolution Medicines, Inc.
$191.43+5.81%
$40.23B
ALNY
Alnylam Pharmaceuticals, Inc.
$198.99-30.54%
$36.28B
INCY
Incyte Corporation
$122.89-3.34%
$23.51B
INSM
Insmed Incorporated
$100.93-2.06%
$23.18B
UTHR
United Therapeutics Corporation
$525.18+0.03%
$22.43B
MRNA
Moderna, Inc.
$57.56+5.74%
$21.45B